News from Across Our Network
Rochester Clinical Research takes great pride in its contribution to Pfizer’s groundbreaking study on Zavzpret (zavegepant) migraine nasal spray, which has recently received FDA approval. This innovative treatment is the first of its...
Doctors working to develop a vaccine for Lyme Disease Patrick Moussignac News10NBCApril 26, 2023 – 5:56 PM ROCHESTER, N.Y. – Lyme disease is one of the most common diseases transmitted by an insect bite. Doctors say it’s...
Rochester Clinical Research recently had the privilege to attend the SCRS Diversity Summit in Austin, TX. We attended numerous informative sessions on the state of diversity in clinical research. Although identifying & retaining...
Swabbing ourselves has become common. At home, Covid-19 tests were made so convenient that people could stay home and find out if they were positive in a matter of 15 minutes. Having that convenience of being able to do the same with other...
Lyme Disease is one of the most common diseases transmitted by an insect bite in the United States. After a tick attaches itself to a host, it can take up to 24-36 hours for the tick to infect the body with Lyme disease. Once infected,...
Hospitals around the country are seeing a rise in RSV (respiratory syncytial virus) cases this season, especially among pediatric patients. RSV is a respiratory virus that attacks the lungs and can be very dangerous in older adults and...
The flu virtually disappeared for two years as the pandemic raged. But influenza appears poised to stage a comeback this year in the United States, according to public health officials. The flu season has started early, and may be severe...
Better Protection against Flu and RSV – mRNA Technology is a Game Changer in vaccine trials at Rochester Clinical Research Rochester Clinical Research (RCR) is currently studying mRNA vaccine development for infectious diseases...